| E-IJD® - SHORT COMMUNICATION |
|
| Year : 2022 | Volume
: 67
| Issue : 2 | Page : 206 |
|
|
Secondary cutaneous mucormycosis post-COVID-19: Case series from a tertiary center
B Abhirami1, Prabhat Kumar1, Dharmendra Kumar Mishra1, Satyendra Prasad Yadav2
1 Department of Dermatology, Venereology, Leprosy, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India
2 Department of Microbiology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India
Correspondence Address:
B Abhirami
Room No: 162, New PG Girls Hostel (Ghaghari Hostel), Rajendra Institute of Medical Sciences (RIMS), Bariatu, Ranchi - 834009, Jharkhand
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijd.ijd_781_21
|
|
|
Background: Mucormycosis is an angioinvasive mucorales fungal infection. Cutaneous type formed 10.5% of cases in India in precovid-19 era. Glucocorticoid-induced immunosuppression and hyperglycemia, reusable oxygen humidifiers in COVID-19 therapy, and preexisting uncontrolled diabetes mellitus contribute to post-COVID-19 mucormycosis. However, for post-COVID-19 cutaneous mucormycosis, sufficient data is not available. Aim: To study factors related to post-COVID-19 cutaneous mucormycosis. Methodology: Clinical and investigation details of six patients admitted in tertiary center with post-COVID-19 cutaneous mucormycosis. Results: Among six patients, three were males and three females; all in 45–60 years age group from districts under tertiary center. Site of eschar was face (four) and lips (two). All six were positive for COVID-19 10–12 days prior to admission for mucormycosis. All had intravenous steroids and supportive humidified oxygen therapy for minimum 1 week under COVID-19 treatment. They presented to emergency with ophthalmic/ENT complaints; subsequently, they developed cutaneous manifestations within 2–3 days. All six had diabetes mellitus, with above 400 mg/dL sugar levels at admission. Conclusion: This study's findings correlated with various studies across the country and elsewhere. Preexisting diabetes mellitus and steroid therapy for COVID-19 increase the risk of mucormycosis. Caution for early diagnosis, maintaining blood glucose levels, and judicious use of steroids for treatment of COVID-19 are indicated.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
